No Data
Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Shanghai Yizhong Pharmaceutical Co., Ltd. 2024 Annual Results Forecast Announcement
Shanghai Yizhong (688091.SH): The net income for 2024 is expected to decrease by 93.81% to 95.05%.
On January 17, Gelonghui reported that Shanghai Yizhong (688091.SH) announced its performance forecast for 2024, expecting to achieve a net income attributable to the owners of the parent company of 8 million to 10 million yuan; a decrease of 93.81% to 95.05% year-on-year. The company expects the net income attributable to the owners of the parent company, excluding non-recurring gains and losses, to be 4 million to 6 million yuan; a year-on-year decrease of 96.28% to 97.52%.
Shanghai Yizhong (688091.SH): has actually repurchased 0.6168% of the shares.
Gelonghui, December 26th丨Shanghai Yizhong (688091.SH) announced that as of the date of this announcement, the company's share repurchase period has expired. The company has actually repurchased 1,274,307 shares, accounting for 0.6168% of the company's total share capital of 206,589,240 shares; the actual amount repurchased is 37,240,964.92 yuan (excluding transaction fees); the highest price for repurchase transactions was 48.00 yuan/share, and the lowest price was 25.54 yuan/share.
Individual Investors Among Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Largest Stockholders and Were Hit After Last Week's 4.8% Price Drop
Shanghai Yizhong (688091.SH): The core product paclitaxel polymer micelle for injection has been included in the national medical insurance list.
On November 28, 格隆汇 reported that shanghai Yizhong (688091.SH) announced that the National Healthcare Security Administration released the notification on "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)" on November 28, 2024 (Healthcare Security [2024] No. 33). The company's core product, paclitaxel polymer micelles for injection, has been included in the part of the National Medical Insurance Catalog Category B management, with the scope of medical insurance payment being: "Limited to combined with platinum-based drugs for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, unresectable locally advanced or metastatic non-liver cancer."